Hillsdale Investment Management Inc. Buys 310 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

Hillsdale Investment Management Inc. raised its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC) by 0.6% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 50,830 shares of the biotechnology company’s stock after acquiring an additional 310 shares during the period. Hillsdale Investment Management Inc.’s holdings in Blueprint Medicines were worth $4,433,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Sei Investments Co. lifted its stake in Blueprint Medicines by 10.0% during the 4th quarter. Sei Investments Co. now owns 70,384 shares of the biotechnology company’s stock valued at $6,139,000 after acquiring an additional 6,411 shares during the period. American Century Companies Inc. lifted its stake in shares of Blueprint Medicines by 3.0% in the 4th quarter. American Century Companies Inc. now owns 839,203 shares of the biotechnology company’s stock worth $73,195,000 after purchasing an additional 24,132 shares during the period. Magnetar Financial LLC bought a new position in shares of Blueprint Medicines in the 4th quarter worth approximately $269,000. Teacher Retirement System of Texas lifted its stake in shares of Blueprint Medicines by 25.7% in the 4th quarter. Teacher Retirement System of Texas now owns 18,760 shares of the biotechnology company’s stock worth $1,636,000 after purchasing an additional 3,840 shares during the period. Finally, Vinva Investment Management Ltd bought a new position in shares of Blueprint Medicines in the 4th quarter worth approximately $170,000.

Insider Activity at Blueprint Medicines

In related news, CEO Kate Haviland sold 1,446 shares of Blueprint Medicines stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $110.24, for a total value of $159,407.04. Following the completion of the sale, the chief executive officer now directly owns 149,378 shares in the company, valued at $16,467,430.72. The trade was a 0.96 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Jeffrey W. Albers sold 15,161 shares of Blueprint Medicines stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $109.53, for a total value of $1,660,584.33. Following the completion of the sale, the director now owns 152,396 shares of the company’s stock, valued at $16,691,933.88. The trade was a 9.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 29,334 shares of company stock worth $3,103,512 over the last three months. 4.21% of the stock is owned by corporate insiders.

Blueprint Medicines Stock Up 0.3 %

NASDAQ:BPMC opened at $88.72 on Friday. Blueprint Medicines Co. has a twelve month low of $80.68 and a twelve month high of $121.90. The company has a market cap of $5.67 billion, a price-to-earnings ratio of -82.15 and a beta of 0.58. The stock has a fifty day simple moving average of $99.47 and a 200-day simple moving average of $93.88. The company has a current ratio of 2.85, a quick ratio of 2.80 and a debt-to-equity ratio of 1.15.

Blueprint Medicines (NASDAQ:BPMC) last released its earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. Analysts anticipate that Blueprint Medicines Co. will post -1.28 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Jefferies Financial Group assumed coverage on shares of Blueprint Medicines in a research note on Monday, March 17th. They issued a “buy” rating and a $135.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and issued a $135.00 price objective on shares of Blueprint Medicines in a research note on Friday, February 14th. Wedbush reiterated an “outperform” rating and issued a $128.00 price objective on shares of Blueprint Medicines in a research note on Friday, February 28th. Stephens restated an “overweight” rating and set a $140.00 target price on shares of Blueprint Medicines in a research note on Thursday, January 2nd. Finally, Needham & Company LLC restated a “buy” rating and set a $133.00 target price on shares of Blueprint Medicines in a research note on Thursday, February 13th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $124.95.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.